GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms GOAL-ARC
- 05 Apr 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2016 study design has been changed from double blind to open label.
- 19 May 2016 Planned initiation date changed from 1 Feb 2016 to 1 Jun 2016.